IMV INC (IMV)
(Delayed Data from NSDQ)
$4.40 USD
+0.70 (18.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.40 USD
+0.70 (18.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
IMV Doses First Patient in the Mid-Stage Study With Keytruda
by Zacks Equity Research
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
Do Options Traders Know Something About IMV Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to IMV stock based on the movements in the options market lately.
IMV INC (IMV) Reports Next Week: What to Expect
by Zacks Equity Research
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV Enters Oversold Territory
by Zacks Equity Research
IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
IMV INC (IMV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy IMV Ahead of Earnings?
by Zacks Equity Research
IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IMV INC (IMV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV Inc. (IMV) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).
IMV Catches Eye: Stock Jumps 10%
by Zacks Equity Research
IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
IMV INC (IMV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate IMV INC (IMV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
by Zacks Equity Research
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
Will IMV INC (IMV) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV INC (IMV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
IMV INC (IMV) delivered earnings and revenue surprises of -33.33% and 175.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will IMV INC (IMV) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate IMV INC (IMV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.